NCT04678648: A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

NCT04678648
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Participants receiving cancer therapy at the time of enrollment.
https://ClinicalTrials.gov/show/NCT04678648

Comments are closed.

Up ↑